Evidence map›Paper›PMID 37375738›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

Lecithin and Chitosan as Building Blocks in Anti-

Lisa Myrseth Hemmingsen, Virginia Panzacchi, Lloyd Mbugua Kangu, Barbara Giordani, Barbara Luppi, Nataša Škalko-Basnet

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Lisa Myrseth HemmingsenDepartment of Pharmacy, University of Tromsø-The Arctic University of Norway, Universitetsvegen 57, 9037 Tromsø, Norway.ORCID 0000-0003-0425-8829
Virginia PanzacchiDepartment of Pharmacy, University of Tromsø-The Arctic University of Norway, Universitetsvegen 57, 9037 Tromsø, Norway.
Lloyd Mbugua KanguDepartment of Pharmacy, University of Tromsø-The Arctic University of Norway, Universitetsvegen 57, 9037 Tromsø, Norway.
Barbara GiordaniDepartment of Pharmacy and Biotechnology, University of Bologna, Via San Donato 19/2, 40127 Bologna, Italy.ORCID 0000-0001-8870-8836
Barbara LuppiDepartment of Pharmacy and Biotechnology, University of Bologna, Via San Donato 19/2, 40127 Bologna, Italy.
Nataša Škalko-BasnetDepartment of Pharmacy, University of Tromsø-The Arctic University of Norway, Universitetsvegen 57, 9037 Tromsø, Norway.ORCID 0000-0002-4301-2840
UiT The Arctic University of Norway · NOUniversity of Bologna · IT

Funding

UiT The Arctic University of Norway 235569
6 · The paper itself

Abstract

The main focus when considering treatment of non-healing and infected wounds is tied to the microbial, particularly bacterial, burden within the wound bed. However, as fungal contributions in these microbial communities become more recognized, the focus needs to be broadened, and the remaining participants in the complex wound microbiome need to be addressed in the development of new treatment strategies. In this study, lecithin/chitosan nanoparticles loaded with clotrimazole were tailored to eradicate one of the most abundant fungi in the wound environment, namely

Indexed as

biocompatibilityC. albicanschitosanefficacy-by-designlipid-based carriersphosphatidylcholinesafety-by-design

Identifiers

PMID37375738
PMCPMC10302193
OpenAlexW4378472362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.